Saturday, July 11, 2026

pharma · Melanoma · Multiple Myeloma

Xijing Hospital

Xijing Hospital clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
4
Drugs
5
Patents
0
Intelligence · Clinical Programs

Xijing Hospital projects

4 ClinicalTrials.gov programs sponsored by Xijing Hospital.

Xijing Hospital has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. BCMA/CD19 Dual-Target CAR-T

    Xijing Hospital

    Multiple Myeloma

    phase 1 mab active

    1 trial
  2. 18F-P3BZA

    Xijing Hospital

    Melanoma

    other active

    1 trial
  3. Folic Acid

    Xijing Hospital

    Stroke

    small molecule terminated

    1 trial
  4. Intraoperative identification method

    Xijing Hospital

    Thyroid Cancer

    other active

    1 trial

Frequently asked questions

How many clinical projects does Xijing Hospital have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.